The effectiveness of IL-1R blockade in the treatment of T2DM and other diseases suggest that additional therapeutics that target IL-1 family cytokines may provide effective strategies to treat other devastating inflammatory disorders. Here, IL1A is linked to type 2 diabetes mellitus.